keyword
MENU ▼
Read by QxMD icon Read
search

Olmesartan enteropathy

keyword
https://www.readbyqxmd.com/read/29571021/linalyl-acetate-prevents-olmesartan-induced-intestinal-hypermotility-mediated-by-interference-of-the-sympathetic-inhibitory-pathway-in-hypertensive-rat
#1
Soonho Kwon, Yu Shan Hsieh, You Kyoung Shin, Purum Kang, Geun Hee Seol
Olmesartan-associated enteropathy (OAE) is a life-threatening pathological condition, but its underlying mechanisms have not been elucidated. Although intestinal hypermotility is frequently accompanied by chronic diarrhea, there have been no studies of olmesartan-induced hypermotility. Intestinal motility should be well regulated by the enteric nervous system, but degeneration of enteric neurons has been reported in patients with chronic diarrheal diseases, such as irritable bowel syndrome, suggesting a connection between OAE and intestinal hypermotility...
March 20, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29457309/severe-intestinal-malabsorption-associated-with-ace-inhibitor-or-angiotensin-receptor-blocker-treatment-an-observational-cohort-study-in-germany-and-italy
#2
Peter Malfertheiner, Claudio Ripellino, Nazarena Cataldo
PURPOSE: The angiotensin II receptor blocker (ARB) olmesartan has been recently associated with sprue-like enteropathy (SLE), a gastrointestinal condition characterized by intestinal malabsorption (IM) and severe diarrhea. Whether the increased risk of SLE is substance-specific or a class effect involving all ARBs is uncertain. The aim of this study is to assess the risk of enteropathy associated with ARBs and angiotensin converting enzyme inhibitors (ACE-i) by using data from large administrative and claim databases...
February 19, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29364200/in-brief-olmesartan-and-sprue-like-enteropathy
#3
(no author information available yet)
No abstract text is available yet for this article.
January 29, 2018: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/29359522/use-of-olmesartan-and-enteropathy-outcomes-a-multi-database-study
#4
Y-H Dong, Y Jin, T N Tsacogianis, M He, P-H Hsieh, J J Gagne
BACKGROUND: Multiple case reports suggest that olmesartan may be linked to sprue-like enteropathy; however, few epidemiological studies have examined this association and results have been mixed. AIM: To assess whether olmesartan is associated with a higher rate of enteropathy vs other angiotensin II receptor blockers (ARBs). METHODS: We conducted a cohort study among ARB initiators in 5 US claims databases representing different health insurance programmes...
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29247793/a-case-of-olmesartan-associated-sprue-like-enteropathy
#5
Kazunori Nagashima, Takehiko Katsurada, Naoya Sakamoto
No abstract text is available yet for this article.
December 13, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29172402/olmesartan-is-not-associated-with-the-risk-of-enteropathy-a-korean-nationwide-observational-cohort-study
#6
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods: Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012...
November 27, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29163738/a-case-of-moderate-sprue-like-enteropathy-associated-with-telmisartan
#7
Aurelio Negro, Loredana De Marco, Valentina Cesario, Rosaria Santi, Maria Chiara Boni, Magda Zanelli
Sprue-like enteropathy associated with olmesartan medoxomil use has been recently reported. Its clinical manifestations include diarrhea, weight loss and malabsorption. Duodenal biopsies show villous atrophy (VA) with or without intraepithelial lymphocytosis and inflammation of the lamina propria. Serology for celiac disease (CD) is negative and gluten-free diet does not result in clinical improvement. Symptoms resolve after olmesartan discontinuation. Follow-up biopsies show recovery/improvement of the duodenum...
December 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28868495/sprue-like-enteropathy-associated-with-olmesartan-an-unrecognized-emerging-drug-induced-enteropathy
#8
Luís Carvalho Lourenço, Joana Carvalho E Branco, Liliana Santos, Alexandra Martins, Jorge Reis
No abstract text is available yet for this article.
November 2016: GE Portuguese Journal of Gastroenterology
https://www.readbyqxmd.com/read/28676728/-olmesartan-associated-enteropathy-attention-to-an-emerging-iatrogenic-phenomenon
#9
J L Modesto Dos Santos, P González Recio, O A Terry López, I Leturia Frade, B Aguiar Losada, J I Elejalde Guerra
Olmesartan is an angiotensin II type 1 receptor blocker commonly used in the treatment of hypertension. Several cases of sprue-like enteropathy associated with the use of this drug have been described which, even with important signs and limitations for the patient, present a full recovery after discontinuing the use of olmesartan. The case of a 64 year-old patient is presented, diagnosed with hypertension, under treatment with olmesartan-amlodipine, with chronic diarrhoea and villous atrophy on intestinal biopsies without diagnostic criteria for celiac disease and with complete remission after suspending discontinuing the use of olmesartan...
July 4, 2017: Anales del Sistema Sanitario de Navarra
https://www.readbyqxmd.com/read/28670240/telmisartan-induced-sprue-like-enteropathy-a-case-report-and-a-review-of-patients-using-non-olmesartan-angiotensin-receptor-blockers
#10
Harshal Surendra Mandavdhare, Vishal Sharma, Kaushal K Prasad, Amit Kumar, Manish Rathi, Surinder S Rana
Recent studies have identified sprue-like illness associated with the use of the antihypertensive agent olmesartan medoxomil. However, whether this condition is specific to the use of olmesartan or is associated with the use of drugs belonging to the class of "sartans" remains to be clarified. A 45-year-old woman with chronic kidney disease along with hypothyroidism and hypertension presented with chronic diarrhea and significant weight loss. Endoscopy of the upper gastrointestinal tract showed scalloping and grooving of the duodenum, and histopathological examination showed subtotal villous atrophy...
July 2017: Intestinal Research
https://www.readbyqxmd.com/read/28670083/olmesartan-associated-enteropathy
#11
Vivian S Ebrahim, Jason Martin, Stacey Murthy, Elizabeth Odstrcil, He Huang, Daniel Polter
Olmesartan, an angiotensin-receptor blocker frequently prescribed for hypertension, has been commercially available since 2002. In 2012, olmesartan-associated enteropathy was described, and the Food and Drug Administration now requires a black-box warning for olmesartan regarding severe diarrhea. The disorder can be life-threatening and often requires hospitalization. We present three cases that represent different aspects of this disorder, as well as some unusual features.
July 2017: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/28437842/autoimmune-like-chronic-hepatitis-induced-by-olmesartan
#12
Sandrine Barge, Marianne Ziol, Jean-Charles Nault
No abstract text is available yet for this article.
December 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28350748/short-article-mortality-and-differential-diagnoses-of-villous-atrophy-without-coeliac-antibodies
#13
Annalisa Schiepatti, Federico Biagi, Giacomo Fraternale, Claudia Vattiato, Davide Balduzzi, Simona Agazzi, Claudia Alpini, Catherine Klersy, Gino R Corazza
OBJECTIVE: Villous atrophy (VA) of the small bowel is mainly related to coeliac disease (CD), whose diagnosis is made on the basis of positive endomysial/tissue transglutaminase antibodies while on a gluten-containing diet in the vast majority of patients. However, VA can also occur in other conditions whose epidemiology is little known. Our aim was to study the epidemiology and clinical features of these rare enteropathies. PATIENTS AND METHODS: Clinical and laboratory data of all the patients with VA directly diagnosed in our centre in the last 15 years were collected and statistically analysed...
May 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28291561/olmesartan-associated-sprue-like-enteropathy-an-emerging-cause-of-drug-induced-chronic-diarrhea
#14
G Solano-Iturri, N García-Jiménez, J D Solano-Iturri, S Blanco-Sampascual
No abstract text is available yet for this article.
January 2018: Revista de Gastroenterología de México
https://www.readbyqxmd.com/read/28289500/olmesartan-induced-enteropathy
#15
Abimbola Adike, Juan Corral, David Rybnicek, Daniel Sussman, Samir Shah, Eamonn Quigley
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss, and nausea. In contrast to celiac disease, tissue transglutaminase is not elevated and there is no response to a gluten-free diet. Including this entity in the differential diagnosis of sprue-like enteropathy is critical for its early diagnosis since replacing olmesartan with an alternative antihypertensive drug can simplify the diagnostic workup and provide both clinical and histologic improvement...
October 2016: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/28079608/mortality-and-differential-diagnoses-of-villous-atrophy-without-coeliac-antibodies
#16
Annalisa Schiepatti, Federico Biagi, Giacomo Fraternale, Claudia Vattiato, Davide Balduzzi, Simona Agazzi, Claudia Alpini, Catherine Klersy, Gino R Corazza
OBJECTIVE: Villous atrophy (VA) of the small bowel is mainly related to coeliac disease (CD), whose diagnosis is made on the basis of positive endomysial/tissue transglutaminase antibodies while on a gluten-containing diet in the vast majority of patients. However, VA can also occur in other conditions whose epidemiology is little known. Our aim was to study the epidemiology and clinical features of these rare enteropathies. PATIENTS AND METHODS: Clinical and laboratory data of all the patients with VA directly diagnosed in our centre in the last 15 years were collected and statistically analysed...
January 11, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28042253/small-bowel-enteropathy-associated-with-olmesartan-medoxomil-treatment
#17
Michail Galanopoulos, Lazaros Varytimiadis, Athanasios Tsigaridas, Pantelis S Karatzas, Emmanuel Archavlis, Nikos Viazis, Christina Vourlakou, Gerassimos J Mantzaris
Sprue-like enteropathy associated with treatment with olmesartan medoxomil, an angiotensin II receptor blocker, has been described recently. Herein, we report two patients who developed chronic severe non-bloody diarrhea, weight loss, and muscle wasting after prolonged use of olmesartan. Histologic and immunohistochemical examination of multiple duodenal biopsies revealed severe villous atrophy. Clinical signs ceased upon drug discontinuation. Physicians should be aware of this enteropathy even if olmesartan has been taken for months or years...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/27822952/sprue-like-enteropathy-associated-with-olmesartan-in-a-patient-with-villous-atrophy-hla-dq2-genotype-and-antinuclear-antibodies
#18
Isidro Machado, María Reolid, Fernando Martínez de Juan, Carmen Martínez Lapiedra, Fernanda Maia de Alcántara
We describe a new case of enteropathy with villous atrophy in a patient suffering from arterial hypertension treated with olmesartan. The molecular and serological studies showed anti-nuclear antibodies (ANA) and haplotype HLA-DQ2 positive, as well as negative results for anti-transglutaminase, anti-endomysium and anti-enterocytes antibodies. A duodenal villous atrophy was suspected by upper gastrointestinal endoscopy, which was confirmed by histopathology. The morphological picture was suggestive of sprue-like enteropathy with severe lymphoid infiltration and predominant T lymphoid cells...
November 2016: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/27803820/seronegative-intestinal-villous-atrophy-a-diagnostic-challenge
#19
Cláudio Martins, Cristina Teixeira, Suzane Ribeiro, Daniel Trabulo, Cláudia Cardoso, João Mangualde, Ricardo Freire, Ana Luísa Alves, Élia Gamito, Isabelle Cremers, Ana Paula Oliveira
Celiac disease is the most important cause of intestinal villous atrophy. Seronegative intestinal villous atrophy, including those that are nonresponsive to a gluten-free diet, is a diagnostic challenge. In these cases, before establishing the diagnosis of seronegative celiac disease, alternative etiologies of atrophic enteropathy should be considered. Recently, a new clinical entity responsible for seronegative villous atrophy was described-olmesartan-induced sprue-like enteropathy. Herein, we report two uncommon cases of atrophic enteropathy in patients with arterial hypertension under olmesartan, who presented with severe chronic diarrhea and significant involuntary weight loss...
2016: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/27754281/hw-04-1-usefulness-of-big-data-in-clinical-research
#20
Rae Woong Park
Big data indicates the large and ever-increasing volumes of data adhere to the following 4Vs: volume (ever-increasing amount), velocity (quickly generated), variety (many different types), veracity (from trustable sources). The last decade has seen huge advances in the amount of data we routinely generate and collect in pretty much everything we do, as well as our ability to use technology to analyze and understand it. The routine operation of modern health care systems also produces an abundance of electronically stored data on an ongoing basis as a byproduct of clinical practice...
September 2016: Journal of Hypertension
keyword
keyword
87609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"